graph EGM comparisons
durvalumab plus tremelimumabtitledurvalumab alonetitletremelimumabtitleCONDOR (DT vs D ; PDL1 TC<25%), 2019 NCT02319044 mHNSCC - L2 - PDL1 negative 133/67CONDOR (DT vs T ; PDL1 TC<25%), 2019 NCT02319044 mHNSCC - L2 - PDL1 negative 133/67

Pathology:  mHNSCC - L2 - PDL1 negative; 

mHNSCC - L2 - PDL1 negative
CONDOR (DT vs D ; PDL1 TC<25%), 2019CONDOR (DT vs T ; PDL1 TC<25%), 2019
durvalumab plus tremelimumab2T1T1
durvalumab alone0T0
tremelimumab0T0